Clinical Trial Update: Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating golidocitinib versus placebo as maintenance therapy for peripheral T-cell lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)

Snippet

Sponsor: Fudan University | Conditions: Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | Status: RECRUITING